NCT00901927 - Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Follicular Lymphoma

Interventions

DRUG

Bendamustine

Starting dose 90 mg/m\^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.

DRUG

Mitoxantrone

10 mg/m\^2 by vein over 15 minutes on Day 2 of each cycle.

DRUG

Rituximab

375 mg/m\^2 by vein over several hours on Day 1 of each cycle.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston